PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18652825-7	2008	A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression.	parthenolide	55-67	stanniocalcin 1	Homo sapiens	181-185	
18652825-8	2008	ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter.	parthenolide	68-80	stanniocalcin 1	Homo sapiens	127-131	
18652825-11	2008	Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity.	parthenolide	50-62	stanniocalcin 1	Homo sapiens	20-24	
18652825-11	2008	Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity.	parthenolide	50-62	stanniocalcin 1	Homo sapiens	120-124